However, NHL is a heterogeneous group and expressions of PD-1 and PD-L1 in tumor cells and cells in the tumor microenvironment (TME) vary across different NHLs as well as within specific lymphoma subtypes, potentially influencing the response to anti-PD-1 therapy. The gene discussed is PDCD1; the disease is lymphoma.